Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
16 févr. 2024 08h00 HE
|
Autonomix Medical, Inc.
Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, Feb. ...
Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
14 févr. 2024 08h05 HE
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate...
Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain
06 févr. 2024 08h50 HE
|
Autonomix Medical, Inc.
First study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer On track to commence enrollment in Q1 2024 THE WOODLANDS,...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event
01 févr. 2024 08h35 HE
|
Autonomix Medical, Inc.
Live moderated webcast with members of the Autonomix management team on Wednesday, February 7th at 10:00 AM ET THE WOODLANDS, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc....
Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024
31 janv. 2024 08h45 HE
|
Autonomix Medical, Inc.
THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio
30 janv. 2024 12h00 HE
|
Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...
Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use
30 janv. 2024 09h05 HE
|
Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...
Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ
29 janv. 2024 08h05 HE
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market THE WOODLANDS, TX., Jan. 29, 2024 (GLOBE NEWSWIRE)...
Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
26 janv. 2024 16h05 HE
|
Autonomix Medical, Inc.
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...